Researchers will use latest imaging techniques to identify biomarkers that will help develop new and more effective treatments
MANHASSET, NY – The Feinstein Institute for Medical Research Scientist Anil Malhotra, MD, was awarded a five-year, $3 million R01 grant from the National Institutes of Health’s (NIH) National Institute of Mental Health (NIMH) to identify biomarkers for treatment-resistant psychosis and schizophrenia.
Dr. Malhotra and his team, in the study, “Connectivity Biomarkers of Clinical Response in Treatment Resistant Schizophrenia,” will assess patients living with treatment-resistant schizophrenia. They’ll use neuroimaging techniques to identify brain patterns and biomarkers in patients. This information will determine if a currently-available schizophrenia treatment option will be beneficial to the patient before ever administering it or if the patient will be resistant to the medication. The biomarkers will also indicate if the medication being given to the patient is effective. In addition, researchers will look at the brain patterns and biomarkers they observe in the imaging to see if they can develop more targeted and effective treatments for psychosis and schizophrenia.
“With modern-day neuroimaging technology, we have the potential to see how the brain is affected by certain medications and how we can better treat conditions of the brain,” said Dr. Malhotra. “I am grateful that the NIH supports this effort and our study with the goal to improve treatment for the 3.5 million patients in the United States who suffer from schizophrenia.”
“Dr. Malhotra has dedicated his career to uncovering the causes and treatment for schizophrenia and the NIH’s support in this new study will help to provide further insight into this often perplexing disease,” said Ping Wang, MD, chief scientific officer of the Feinstein Institute.
About The Feinstein Institute
The Feinstein Institute for Medical Research is the research arm of Northwell Health, the largest healthcare provider in New York. Home to 50 research laboratories and to clinical research throughout dozens of hospitals and outpatient facilities, the 3,500 researchers and staff of the Feinstein Institute are making breakthroughs in molecular medicine, genetics, oncology, brain research, mental health, autoimmunity and bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we empower imagination and pioneer discovery, visit FeinsteinInstitute.org.
For media inquiries, please contact:
Phone: +1 (516) 465-7917